Clinical Trial Details


Research Study Summary

BHLEX analysis for all modality atrial fibrillation ablation for safety and efficacy – AFIB Registry


Atrial fibrillation affects approximately 2 million Americans according to the American Heart Association. This patient population comprises a substantial portion of patients seen at Baptist Health Lexington. Means of treatment includes pharmacological therapy for controlling both the rate and rhythm. In many cases, also anticoagulants are also necessary to prevent against thrombolytic events and stroke. These medications have inherent side effects that often impinge on patient quality of life. Often they are not enough to adequately control atrial fibrillation.

Another mode of treatment is ablation of the left atrium and/or pulmonary veins. Modalities of ablation, most using radio frequency or cryo-ablation technology, continue to evolve as research better identifies the etiologies associated with all categories of atrial fibrillation. Recurrence of atrial fibrillation is high among this patient population. Sources vary with mixed success reported between 50-70%.

Tracking the BHLEX atrial fibrillation ablation patient experience will offer data on percentage of successes and recurrences for various modalities, such as pulmonary vein isolation (PVA), Topera - Focal Impulse Rotor Modulation (Narayan, et al), nMARQ, simultaneous multiple site ablation (Biosense Webster, Inc.), and other modalities as they are used at this facility. By analysis of successes and recurrences associated with each modality, we may learn which procedure facilitates the best results according to patient population and AF category. We may closely follow adverse events peri- and post- procedure, in order to improve patient outcomes.

To Learn more

CW ID: 216040
Date Last Changed: June 13, 2016

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Facility Type


  • All patient who undergo a curative ablation modality for all categories of atrial fibrillation.
  • Patients who have undergone a curative ablation and then undergo a complete AV node ablation for failure and rate control
  • Patients over 18 years of age
  • All patients who do not undergo any modality of ablation for all categories of atrial fibrillation.
  • Patients with atrial fibrillation who undergo an AV node ablation for rate control, unless patient has previously had a curative procedure attempt, in which case these patients will be followed.

More Info

Track patients from procedure through follow-up clinic visits and atrial fibrillation hospitalizations for
  • Procedure success / failure
  • recurrence of clinical arrhythmia
  • onset of other arrhythmia(s)
  • occurrences of re-ablation with modality used
  • adverse events through all post procedure follow-up visits.


Feather Wafford, Baptist Health Lexington Research Regulatory Coordinator
Baptist Health Clinical Research Center & Lexington Cardiac Research Foundation
1740 Nicholasville Rd
Lexington, KY 40503
Phone: 859-260-6066
Fax: 859-260-4151

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.